Next Article in Journal
Role of Neuroendocrine, Immune, and Autonomic Nervous System in Anorexia Nervosa-Linked Cardiovascular Diseases
Next Article in Special Issue
Strategies and Challenges to Improve Cellular Programming-Based Approaches for Heart Regeneration Therapy
Previous Article in Journal
Adenosine Metabolism in the Cerebral Cortex from Several Mice Models during Aging
Previous Article in Special Issue
Human Cell Modeling for Cardiovascular Diseases
Open AccessReview

Preconditioned and Genetically Modified Stem Cells for Myocardial Infarction Treatment

Department of Medicine, School of Medicine, Nazarbayev University, Nur-Sultan 010000, Kazakhstan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(19), 7301; https://doi.org/10.3390/ijms21197301
Received: 4 September 2020 / Revised: 25 September 2020 / Accepted: 25 September 2020 / Published: 2 October 2020
(This article belongs to the Special Issue Cell Programming for Cardiovascular Disease Modeling and Therapy)
Ischemic heart disease and myocardial infarction remain leading causes of mortality worldwide. Existing myocardial infarction treatments are incapable of fully repairing and regenerating the infarcted myocardium. Stem cell transplantation therapy has demonstrated promising results in improving heart function following myocardial infarction. However, poor cell survival and low engraftment at the harsh and hostile environment at the site of infarction limit the regeneration potential of stem cells. Preconditioning with various physical and chemical factors, as well as genetic modification and cellular reprogramming, are strategies that could potentially optimize stem cell transplantation therapy for clinical application. In this review, we discuss the most up-to-date findings related to utilizing preconditioned stem cells for myocardial infarction treatment, focusing mainly on preconditioning with hypoxia, growth factors, drugs, and biological agents. Furthermore, genetic manipulations on stem cells, such as the overexpression of specific proteins, regulation of microRNAs, and cellular reprogramming to improve their efficiency in myocardial infarction treatment, are discussed as well. View Full-Text
Keywords: myocardial infarction; stem cell therapy; stem cell preconditioning; genetic modification; cell reprogramming; stem cell differentiation myocardial infarction; stem cell therapy; stem cell preconditioning; genetic modification; cell reprogramming; stem cell differentiation
Show Figures

Graphical abstract

MDPI and ACS Style

Raziyeva, K.; Smagulova, A.; Kim, Y.; Smagul, S.; Nurkesh, A.; Saparov, A. Preconditioned and Genetically Modified Stem Cells for Myocardial Infarction Treatment. Int. J. Mol. Sci. 2020, 21, 7301. https://doi.org/10.3390/ijms21197301

AMA Style

Raziyeva K, Smagulova A, Kim Y, Smagul S, Nurkesh A, Saparov A. Preconditioned and Genetically Modified Stem Cells for Myocardial Infarction Treatment. International Journal of Molecular Sciences. 2020; 21(19):7301. https://doi.org/10.3390/ijms21197301

Chicago/Turabian Style

Raziyeva, Kamila; Smagulova, Aiganym; Kim, Yevgeniy; Smagul, Saltanat; Nurkesh, Ayan; Saparov, Arman. 2020. "Preconditioned and Genetically Modified Stem Cells for Myocardial Infarction Treatment" Int. J. Mol. Sci. 21, no. 19: 7301. https://doi.org/10.3390/ijms21197301

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop